LAUSR

taneous occurrence of DLBCL and FL (DLBCL/FL) in the same lymph node (LN). These pts are treated as DLBCL. The outcome of these pts was not described yet, and these pts are usually excluded from DLBCL and FL trials. Methods: Data of newly diagnosed pts have been prospectively collected in the Lymphoma Project NiHiL since 1999. Altogether, 201 DLBCL/FL pts diagnosed in 2002 to Jan 2016 were confirmed by histopathological review. The percentage of DLBCL and FL components was established. The clinical characteristics, treatment and outcome were analysed. Two comparator groups were selected, the DLBCL patients of GC subtype (Hans algorithm) (n 304, dg 2005 to Jan 2016) and FL pts (n 1420, dg 2005 to Jan2016), both groups treated by Rituximab (R) chemo. Outcome of these subgroups was compared by logrank test. Results: Out of 201 DLBCL/FL pts, grade of FL part was evaluated as G1‐G3A in 87 (43.3%), G3B in 89 (44.3%) and G3 without specification in 25 (12.4%). The proportion of DLBCL component was ≥50% in 105 pts (55.9%). The median age was 61 years (29 to 97) and male/female ratio 1.12/1. The IPI score was low and lowintermed (LI) vs highintermed (HI) and high in 58.7% vs 41.3% resp. The FLIPI score was good, intermed and high in 33.0%, 21.0% and 46.0% resp. R was used in 181 pts (87.9%), CHOP in 166 (82.6%) and other chemo in 35 (17.4%) pts. The OS and PFS probability at 5 years was 77.2% and 66.4% resp. with median follow‐up 5.6 year. The DLBCL GC comparator group had median age 64.5 years (19 to 88), HI and high risk IPI was found in 47.8% pts. The FL comparator group had median age 59 years (27 to 90); FLIPI good, intermed and high risk score were in 22.2%, 29.3% and 48.5% resp. The cohorts were not different from the DLBCL/FL group in terms of patients characteristic. The 5‐year OS probability for DLBCL/FL1‐3A, DLBCL/FL3B, DLBCL GC and FL cohorts were 76.1%, 81.8%, 79.9% and 86.5% resp. (p = 0.001; Figure 1). The 5‐year PFS probability for DLBCL/FL1‐3A, DLBCL/ FL3B, DLBCL GC and FL cohorts were 63.3%, 71.8%, 71.6% and 62.8% resp. (p = 0.14). FL had statistically better outcome for OS. RM was used in 20 pts, in both subgroups DLBCL/FL1‐3A (n 10) as well as DLBCL/FL3B (n 8) and DLBCL/FL 3 (n 2). When compared to pts without RM, there was identified a trend for better PFS in RM cohort with 5‐year PFS 89.5% vs cohort w/o RM with 5‐year PFS 74.4% (p = 0.15; Figure 2). Forty‐six relapses in DLBCL/FL pts were observed, 19 pts with histological verification of relapse. Out of these, 7 pts (36.8%) relapsed as DLBCL, 6 (32.0%) as FL, 5 pts (10.8%) as DLBCL/FL and 1 pts into B NHL. Conclusions: Our analysis shows that DLBCL/FL behaves as GC DLBCL with the same OS probability. RM for patients with DLBCL/ FL G1‐G3A might improve the outcome, but more data are needed. Supported by grant of Ministry of Health of the Czech Republic MZ VES 16‐31092A.